1. 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. (September 2015) Authors: Tolcher, A.; Harb, W.; Sachdev, J.; Papadopoulos, K.; Bordoni, R.; Chai, F.; Larmar, M.; Savage, R.; Abbadessa, G.; Saleh, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors. (September 2015) Authors: Hidalgo, M.; Boni, V.; Tolcher, A.; Smith, L.; Cubillo, A.; Rasco, D.; Calvo, E.; Amaya, A.; Ordoñez, E.; Patnaik, A.; Cerda, S.; Coronado, C.; Fudio, S.; Miguel-Lillo, B.; Prados, R.; Ortega, O.; Soto-Matos, A.; Papadopoulos, K.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). (September 2015) Authors: Ejadi, S.; Vogelzang, N.; Sartor, A.; Clark, R.; Tolcher, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage. (October 2022) Authors: Ulahannan, S.; Johnson, M.L.; Park, H.; Vandross, A.; Uttamsingh, S.; Li, J.; Syed, M.; Tolcher, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Archival vs fresh tumor samples for assessing the gene expression of NaPi2b and immune-related genes in the Phase 1b study of Upifitamab Rilsodotin (UpRi) in platinum-resistant ovarian cancer. (October 2022) Authors: Lu, M.; Shaw, P.; Richardson, D.; Hamilton, E.; Bernardo, P.; Bradshaw, C.; Tolcher, A.; Mosher, R. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors. (October 2022) Authors: Meric-Bernstam, F.; Eder, J.P.; Vandross, A.; Gara, M.; Gayle, S.; Pearson, P.; DeCillis, A.; Tolcher, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Development and characterization of HER2+ T-DM1-resistant breast cancer PDX models. (December 2016) Authors: Wick, M.; Moriarty, A.; Quinn, M.; Vaught, T.; Rundle, M.; Tolcher, A.; Rasco, D.; Patnaik, A.; Papadopoulos, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Establishment and characterization of a hormone dependent, PSA/PSMA positive prostate PDX model. (December 2016) Authors: Wick, M.; Quinn, M.; Mangold, A.; Gamez, L.; Diaz, A.; Vaught, T.; Reyna, J.; Tolcher, A.; Rasco, D.; Patnaik, A.; Papadopoulos, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Preliminary results from HERKULES-1: a phase 1b/2, open-label, multicenter study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors. (October 2022) Authors: Wang, J.; Johnson, M.; Barve, M.; Pelster, M.; Chen, X.; Li, Z.; Gordon, J.; Reiss, M.; Pai, S.; Falchook, G.; Tolcher, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗